PyramIDH
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- NCT06465953 ↗
- Recruiting
- Institut de Recherches Internationales Servier
- Focused
We haven't built an HCP commentary report on PyramIDH (ivosidenib and azacitidine in Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PyramIDH so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (PyramIDH Study)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS); Myelodysplastic Syndromes (MDS)
- Interventions
- Ivosidenib; Azacitidine
- Arms
- Ivosidenib monotherapy · Experimental
- Azacitidine monotherapy · Experimental
- Enrollment
- 48 (estimated)
- Primary outcomes
- Number of participants achieving CR and PR by 4 months
- Sponsor
- Institut de Recherches Internationales Servier with Servier Bio-Innovation LLC
- Start
- Dec 3, 2024
- Primary completion
- Nov 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06465953 · updated Sep 3, 2026